Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
STLT is current in Nevada, SOS, has a new Director CEO, held the shareholder meeting March 2021, notices were sent to all shareholders by mail and email that were shareholders, and here is a first look at the new CEO of STLT. Awesome credentials.
Now the question is will the SEC work with him.
For some reason the SEC notice had not reached him, SEC it seems may not have done their DD and checked Nevada updates for where and how to reach the new CEO to get that last notice to him? Just a guess. I got the notice from you here, and I sent it the CEO Destiny Aigbe.
I do not recommend buying shares at this time, until any SEC issues are fixed.
I have of lot of money invested in retail shares here going back to 2010, so I hope the SEC does not screw me over for being bag a holder.
Now that the firm has a real CEO again, one with credentials most folks would die for, figuratively speaking that is, I hope the SEC will let him Merge in a new company....and save the company.
https://www.aigbelaw.com/attorneyprofile
Destiny Aigbe
Mr. Aigbe focuses his practice on a wide range of matters, including matters arising from financing of small private and public firms to broker-dealer disputes and investment fraud. Mr. Aigbe's practice includes public and private offerings, broker-dealer and investment banking matters, secondary market transactions, venture and private equity capital investments and mergers and acquisitions.
His clients consist of public and private companies, broker-dealers, investment banking firms and individual entrepreneurs.
Mr. Aigbe also represent issuers, underwriters, and placement agents in private and public securities offerings, including reverse mergers, initial public offerings (IPOs), secondary offerings, private placements, debt offerings, private investments in public equity (PIPEs), and equity crowdsourcing.
Mr. Aigbe earned his B.S. in Finance with honors at the University of Maryland's Robert H. Smith School of Business. Mr. Aigbe then worked for Bank of America's Investment Banking Division where he participated in mergers and acquisitions in the energy and power sectors.
Mr. Aigbe attended and graduated from Vanderbilt University Law School where he focused on the Law of Finance and Mergers & Acquisitions and earned a certificate in Law and Business.
Mr. Aigbe has been an avid investor for the last 10 years.
Mr. Aigbe has served the US government for part of his career. He has worked for the US Department of State where he handled employment law matters.
Mr. Aigbe was in Baghdad in 2012.
Mr. Aigbe has also worked as a transaction and contracts manager for the National Institutes of Health (NIH).
Mr. Aigbe was involved in several Small Business Innovation Research contracts and helped entrepreneurial biotechnology, nanotechnology, pharmaceutical, and data analytics firms receive funding and grow.
Mr. Aigbe also worked for the US Department of Defense.
Education
VANDERBILT UNIVERSITY LAW SCHOOL
Juris Doctor, 2010
UNIVERSITY OF MARYLAND, COLLEGE PARK
B.S., Finance with honors, 2007
Activities & Affiliations
• The Bar Association of the District of Columbia, Member
• Washington Area Volunteer Lawyers for the Arts, Volunteer Attorney
Bar Admissions
• District of Columbia, State of Colorado, US District Court for the District of Columbia,
US District Court for the District of Colorado
Licensed in District of Columbia,
State of Colorado,
US District Court for the District of Columbia,
US District Court for the District of Colorado,
with pro hac vice Admission for the State of Maryland and Virginia.
Our going public, securities regulation, and capital raising practice serves clients all over the United States including, but not limited to: Atlanta, Austin, Baltimore, Boston, Charlotte, Chicago, Cincinnati, Cleveland, Dallas–Fort Worth, Denver, Detroit, Honolulu, Houston, Los Angeles, Miami, New York City, Philadelphia, Phoenix, Pittsburgh, Portland, San Bernardino-Riverside, San Diego, San Francisco, Seattle, St. Louis, Tampa–St. Petersburg, and Washington, D.C.
Our going public, securities regulation, and capital raising practice serves clients all around the world in countries including, but not limited to:
Australia,
Argentina,
Canada,
Chile,
Brazil,
China,
Denmark,
Dubai,
France,
Ghana,
Germany,
Ireland,
Italy,
India,
Israel,
Japan,
Korea,
Nigeria,
Netherlands,
New Zealand,
Norway,
Panama,
Spain,
Switzerland,
Sweden,
Saudi Arabia,
Singapore,
South Africa,
Thailand,
Turkey,
United Arab Emirates,
United Kingdom,
and Qatar
Here is the text of the Proxy, that shows the dates and times, the Shareholders meeting was March 24th, 2021
"PROXY STATEMENT FOR THE 2021 SPECIAL MEETING OF STOCKHOLDERS
GENERAL INFORMATION
This proxy statement contains information related to the 2021 Special Meeting of Stockholders (“Special Meeting”) of Spotlight Innovation, Inc., a Nevada corporation (“we”, “us”, “our”, or “the Company”), to be held remotely on Wednesday, March 24, 2021 at 6:30 AM EST and at any postponements or adjournments, thereof. The approximate date of mailing for this proxy statement is February 1, 2021. You are invited to attend the Special Meeting, and we request that you vote on the proposals described in this Proxy Statement. You do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card.
The Company proxy statement in connection to this meeting can be accessed online at: https://tinyurl.com/STLT2021
Record Date
Our Board of Directors has set January 15, 2021 as the record date (the “Record Date”) for the Special Meeting.
Only holders of record of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”) or Preferred Stock at the close of business on the Record Date will be entitled to notice of, and to vote at, the Special Meeting or at any adjournment or postponements thereof.
On the Record Date there were 34,290,934 shares of Common Stock and 1,500,000 Series D Preferred Stock issued and outstanding. Each stockholder is entitled to one vote for each share of Common Stock registered in his or her name on the record date.
The voting rights of the holders of Series D Preferred Stock are as follows:
Holders of the Series D Preferred Stock, with such votes to be counted together with all other shares of capital stock having general voting powers and not separately as a class, shall have the right to vote in an amount equal to ninety point zero one percent (90.01%) of the total vote with respect to any and all matters presented to the stockholders of the Company for their action or consideration
The holders of the Series D Preferred Stock and Common Stock shall, voting together as a single class, shall be entitled to elect all of the corporation’s directors and remove from office such directors and fill any vacancy by the cause resignation, death or removal of such directors, subject to the right of the Board of Directors to fill the vacancy pursuant to applicable law.
Voting rights of the holders of Series D Preferred Stock may be exercised in writing or by calling a special meeting in accordance with methods required to call such meetings by stockholders.
Voting by Proxy
If your shares are registered directly in your name with VStock Transfer, LLC, our transfer agent, you are considered a stockholder of record. As a stockholder of record at the close of business on the Record Date, you can vote in person at the Special Meeting or you can provide a proxy to be voted at the meeting by signing and returning the enclosed proxy card. If you submit a proxy card, we will vote your shares as you direct. If you submit a proxy card without giving specific voting instructions, those shares will be voted as recommended by the Board of Directors, which means your shares will be voted “For” all the nominees to the Board of Directors in Proposal I. If any other matter is properly presented at the Special Meeting, your proxy (i.e., one of the individuals named on your proxy card) will vote your shares using their best judgement.
If your shares are held in a stock brokerage account or otherwise by a nominee (that is, in “street name”), you will need to obtain a proxy form from the institution that holds your shares and follow the instructions included on that form regarding how to instruct your broker to vote your shares. If you do not give instructions to your broker, your broker can vote your shares with respect to “discretionary” items, but not with respect to “non-discretionary” items.
Discretionary items are proposals considered routine under the rules of the New York Stock Exchange on which your broker may vote shares held in street name in the absence of your voting instructions. On non-discretionary items for which you do not give your broker instructions, the shares cannot be voted and will be treated as broker non-votes.
Required Vote
Proposal I – Election of Directors
Directors are elected by a plurality of the affirmative votes cast by those entitled to vote at the Special Meeting. Broker non-votes will count towards the quorum but will have no effect on the outcome of the vote.
Revocation of Proxy
Your execution of the enclosed proxy will not affect your right as a stockholder to attend the Special Meeting and to vote in person. Any stockholders giving a proxy has the right to revoke it at any time by either (i) a later-dated proxy, (ii) a written revocation sent to and received by the Secretary of the Company prior to the Special Meeting, or (iii) attendance at the Meeting and voting in person. If your shares are held in street name, you must follow the instructions provided by your broker or bank.
Cost of Proxy Solicitation
We will pay for the entire cost of soliciting proxies by our Board of Directors. In addition to the solicitation of proxies by mail, solicitation may be made personally or by telephone or electronic communication by our directors, officers and employees, none of whom will receive additional compensation for these services. We will reimburse brokers and other nominees for their reasonable out-of-pocket expenses incurred in connection with distributing forms of proxies and proxy materials to the beneficial owners of our Common Stock.
PROPOSAL I
ELECTION OF DIRECTORS
There is one nominee for election to the Company’s Board of Directors. The name of the person who is a nominee for director and his positions and offices with the Company are set forth in the table below. The director to be elected will hold office until his successor is elected and duly qualified, or until such director’s earlier death, resignation, or removal.
Directors are elected by a plurality of the votes present in person or represented by proxy and entitled to vote at the Special Meeting. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominee named below. In the event that any nominee should be unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee as the Board of Directors may propose. The nominee listed below has been nominated for and has agreed to stand for election and the Board has no reason to believe that the nominee will be unable to serve.
Destiny Aigbe as President, CEO, Secretary, Treasurer and Director
Mr. Destiny Aigbe, a Colorado-native currently living in the Washington, D.C. area, focuses his practice on a wide range of securities and corporate matters. His clients consist of public and private companies, investment banking firms and individual entrepreneurs. Destiny also represents issuers, underwriters, and placement agents in private and public securities offerings, including reverse mergers, initial public offerings (IPOs), secondary offerings, private placements, debt offerings, private investments in public equity (PIPEs), and equity crowdsourcing.
Destiny earned his B.S. in Finance with honors at the University of Maryland’s Robert H. Smith School of Business. He then worked for Bank of America’s Investment Banking Division, where he participated in mergers and acquisitions in the energy and power sectors. He graduated from Vanderbilt University Law School, where he focused on the Law of Finance and Mergers & Acquisitions and earned a certificate in Law and Business.
Upon graduating law school, Destiny gained experience in government contracts and employment law in various federal agencies. As part of his service at the U.S. State Department, Destiny briefed U.S. Ambassadors, diplomats, and locally-employed staff in Baghdad, Iraq and Amman, Jordan in 2012 on employment laws. After the State Department, Destiny worked as a transaction and contracts manager for the National Institutes of Health. He was involved in several Small Business Innovation Research contracts and helped entrepreneurial biotechnology, nanotechnology, pharmaceutical, and data analytics firms receive funding and grow. For several years, Destiny volunteered on the board of directors of a non-profit organization helping the homeless population in Northern Virginia.
Term of Office
Our directors are appointed to hold office until removed from office in accordance with our bylaws.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” ALL OF THE NOMINEES IN PROPOSAL I
CORPORATE GOVERNANCE
The Board’s Role in Risk Oversight
The Board of Directors has an active role in overseeing management of the Company’s risks. The Board regularly reviews information regarding the Company’s credit, liquidity, financial condition and operations, as well as the risks associated with each.
Stockholder Communications with the Board of Directors
Stockholders may contact members of the Board of Directors by writing to them care of Spotlight Innovation, Inc., 1101 Connecticut Ave Suite 450, Washington, DC, 20036, USA.
Code of Ethics
We have not adopted a formal code of ethics statement.
The Board of Directors evaluated the business of the Company and the number of employees and determined that since the business is operated by a small number of persons who are also the officers and directors, general rules of fiduciary duty and federal and state criminal, business conduct and securities laws are adequate ethical guidelines.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Listed below is the information as of January 15, 2021, regarding the beneficial ownership of our common stock by each person who is known by us to beneficially own more than 5% of our shares of common or preferred stock; and each named executive officer, each director and all of our directors and executive officers as group.
The number of shares beneficially owned, and the percentage of shares beneficially owned are based on 34,290,934 shares of Common Stock and 1,500,000 Series D Preferred Stock issued and outstanding as of January 15, 2021.
Each shareholder listed below possesses sole voting and investment power with respect to the shares shown.
The address of our directors and officers is 1101 Connecticut Ave Suite 450, Washington, DC, 20036, USA.
Name of beneficial owner
Number of Shares Beneficially Owned
Percentage of
Class
Destiny Aigbe, President
1,500,000 Series D Preferred Stock
100%
For the purposes of the information provided above, shares that may be issued upon the exercise or conversion of options, warrants and other rights to acquire shares of our common stock that are exercisable or convertible within 60 days following January 15, 2021, are deemed to be outstanding and beneficially owned by the holder for the purpose of computing the number of shares and percentage ownership of that holder, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person.
DIRECTOR COMPENSATION
Compensation of Directors
In the fiscal year 2020 we have not paid director fees.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE
None of the following parties has, since the beginning of our last fiscal year or during the preceding fiscal year, had any material interest, direct or indirect, in any transaction in which the amount involved exceeded the lesser of $120,000 or one percent of our average total assets at year-end for the last two completed fiscal years:
Any of our directors or officers;
Any person who beneficially owns, directly or indirectly, shares carrying more than 5% of the voting rights attached to our outstanding shares of common stock;
Any member of the immediate family (including spouse, parents, children, siblings, step-parents, step-children and in-laws) of any of the above persons or any person (other than a tenant or employee) sharing the household of any of the above persons.
OTHER MATTERS
Our Board of Directors does not know of any other matters that are to be presented for action at the Special Meeting other than those described in this Proxy Statement. Should any other matter come before the Special Meeting, however, the persons named in the enclosed proxy will have discretionary authority to vote all proxies with respect to such matters in accordance with their judgment.
By Order of the Board of Directors
Destiny Aigbe
President
January 29, 2021
Looks like the Nevada SOS data on STLT is current. See the screen shot below.
Not sure why the SEC has not used that latest SOS data to contact the attorney directly that is the new director and CEO that US brokers recently notified shareholders of the pending Shareholders meeting and their chance to vote, with a copy of the proxy.
I did some checking and found the broker notice link, here is the proxy notice all the brokers of $STLT shares sent out.
That shareholders meeting already took place.
https://docs.google.com/document/d/e/2PACX-1vSk4Tftk9Ls8hW542TZSWvap0lkZQvQU20Nqs5HYZkJg2D1EywvSi4h7UXZ5rdN2gs8YVh6_AH3fMYo/pub
Interesting update, thanks.
BTW, you may not know(?) that the brokers sent electronic notices of a shareholders meeting to share holders of record (like me) that there is shareholders meeting tomorrow, where a new person with ownership of all the preferred share voting shares, has 90% vote control via those shares, will vote himself in as the new sole Director.
By the end of Tomorrow he will be the sole director of STLT and will name himself the new CEO.
It is safe to assume he has good reason for that.
Any wants to sell, I am still on the bid.
https://www.sec.gov/litigation/opinions/2021/34-91440.pdf
I hope those were not short shares some one sold me this morning LOL
So what is the score here with STLT these days, they all going to kiss and make up and some how save this?
Or waste time and money throwing darts at each other???
Asking for a friend, LOL.
You seeing this?
Seems I am back up 1 Million % LOL
52 week low .000001/share
I think the law firm hunting for clients made that recent post in stealth mode. Who knows.
I found all the court case and related links.
And yes I did get about 10 years of snake oil ( Venodol )rub on pain killer STLT from Walmart that manufactured before it went dark
Never would have know it existed had I not been a shareholder.
Got a court case number, and link, which state and federal or state court???
Find PRINCIPAL SECURITIES, INC., Petitioner, vs. SANJEEV AGARWAL, RAJSHRI AGARWAL, and TECHNOCHEM INTERNATIONAL, INC. It will all center around John M. Krohn
Yes, this is one of the oddest ones I have seen and been in.
Makes me think some key people, or person(s) died, or something.
The insiders got hurt one hell of lot more than we did, as they had millions of dollars invested and still held about 2/3 rds of the OS of STLT. One would think they would have filed and made up some BS and converted their shares and sold being OTC to get some of their investments back.
Majority of my invested dollars go back as far 2009 on this one.
One would have thought they would have brought in a new team and assets if nothing else.
Very strange. Last time I called the voice mail stilled work, the phone still worked, but they were 100% gagged, would not talk by phone or email...which was no surprise being so late..
"They could have gone dark with a form 15 or at least worked with the SEC,"
That is what I have been told. I think I had about $10K in here going back 10 years.
sorry for your loss my man, same for me, lost about $6700 even with some good trading, when it goes to zero it doesnt matter what you paid per share, only your net amount of money spent. They could have gone dark with a form 15 or at least worked with the SEC, who knows what they did, they took down their web site, stopped responding to emails, this is what happens when you do that. Glad you got a working product for your health issues, thats clearly a benefit.
I invested in STLT when it was a real biotech. It and the prior company were both real. No need to go into details.
STLT brought a product to market after I had invested (thus my investing helped get the product to market) that helped me avoid deadly toxic pain killers I needed to battle my RA. RA that nearly killed me in 2014....long story.... The STLT rub on pain killer Venodol, was (still is at times, I bought a bunch enough to last me years, I like to be prepared, like to have back up plans LOL, never know when the FDA (Federal Drug Alliance, LOL) might get highjacked by some henious demon or antichrist LOL) and it was and is an awesome help to me at times.....long story.
I have invested in private firms, started my own private firms, nearly gone public myself (decided it was too much hassle and a waste of my money). Sold my 1/3 owner ship of a private firm when I was only 25, a Tech firm I built in just 2 years, in the 1970s. Investing is not new to me. Building and starting firms is not new to me. Doing consulting for BODs and CEOs is not new me.
All investments are risky. Even big board stocks. Ask Enron folks. BTW, I never invested in Enron, and walked away for a chance to sell my firm to them, because it knew it was scam....
With stocks, like STLT I not only invest to make money, I also invest in new tech/tech firms who bringing real, new tech to market, I invest to help them get the tech to market. I hope to make money in the process.
Some techs I invest in because for me, trying to get the new tech, or help get the new tech to market is the right thing to do, ethically, for me.
One of the problems with today's world and market is no one seems to care about anything but running scams to make money.
In 2009, a stock similar to this one, STLT, did a belly flop.
I owned shares before it died. I bought more at the bottom on it, road out the R/S at .001 , and in days it was uplisted from OTC as a dead company to Nasdaq as Tgtx at $4/share, with 10 mil in new cash and a licensed new drug from Europe as a brand new biotech, with a new CEO that had already run a Nasdaq biotech firm, and in 6-9 months it was an $18 stock with Crammer on Mad Money pumping it. I sold when Crammer showed up, LOL.
I was the lone ranger on that one too in 2009.
Last I looked, recent weeks, Tgtx was trading 10 years later on Nasdaq at $20 (apx) a share. In 2009 the ticker was Mhan. My post record is still here on Ihub for Tgtx when it was Mhan in 2009
Shit happens, miracles happen in OTC.
Lotteries are near zero probability of winning scams. Because I know how to spot most scams, My success rate in stocks that I have done real investments in has been way better in OTC than in Big board stocks. I was up $500,000 in one in 2014.... And it was also one I bought the knife on at near death in Dec 2011, And it was a real game changer tech stock that could have have had a huge impact on solving the CO2 green house gas problem, if GE had not slipped in and sacked it late in the game.. in 2017. Interestingly enough one of the top dogs at the US DOE 30 years ago had warned me how crooked GE was and told me not to let them any where near my technology. 26 years later GE proved he was right.
My point is being lawful does not make it right. And once again regs issued by government agencies based are now laws, The Exchange Act is a law, and act of Congress, the Regulations created by the SEC are not Congressional laws, they are agency Regs.
EPA has had enforceable regs issued one day, been dragged into court for 10 years to stall/delay/kill enforcement and later been turned over and rescinded by later administrations. Regulations and guidance documents by federal agencies are not laws.
There is a reason we have courts. Judges decide what the law is. Supreme court just settled one battle going on for ages it seems, over a lawful subpoena of some ones tax returns. Took the Supreme court to decide what the law was, not agency folks, as the agency folks of 2 agencies were locked in battle over what was lawful and what was not.
Anyway, thanks for the discussion. I think we have beat this one nearly to death LOL.
Thanks for the chat!
By the way, regulations are not laws. SEC enforces regulations that the SEC writes, that are its interpretation of the law written by congress.
The Exchange Act is a law written by Congress.
Only a judge can decide if the reg is legitimate and if it was breaking the law. Most people and companies do not have the resources to go to court.
For God's sake. What would STLT's defense be? It could hardly dispute the fact that it's delinquent with its filings.
What is wrong with being able to keep and hold my shares till hell freezes over in hopes the company survives and gets going again?
That is your choice. And your risk, since as you say, you knew the company was delinquent.
What gives the SEC the right to destroy my shares or the value of them?
The Exchange Act.
I think lotteries should be illegal.
Then why on earth do you invest in penny stocks?
LOL, I have yet to find a company on this planet that does not "break the law". All STLT did was nothing. They are getting castrated for doing nothing.
Shall I list the ones that get away with murder world wide and trade on the big boards here like nothing is wrong?
They do not get their shares revoked.
Novartis committed felony fraud for years going way back and got fined over $100 mil dollars, Their shares still trade.
MM-CDEL got nailed for fraud, for FRAUD, and was allowed to keep stealing money as the top dog market maker.
https://www.sec.gov/news/pressrelease/2017-11.html
I have evidence the SEC is doing a lousy job and taking way too long. Perhaps part of the problem is a lack of funding and new legislation to do a better job, being blocked by folks paying off the congress to sit back and take campaign money. Big board banks that the SEC lets trade are living off of loans to toxic loan pay day scams milking people with old MOB-style shark loans with 2000% + interest per year loans, or is per month??
"That is total bullshit. The SEC has in fact been doing a good deal to try to get the toxic funders out of the market in the last six years and more."
There are so many old laws on the books, that have never been removed, a cop can arrest people and select 50-100 BS charges against them and arrest them and lock them up for the craziest shit.
Be glad to share examples? I once successfully defended a company and its owner from an out of control special kind of cop..... that thought he was judge and jury .... Been there done that. He was 100% wrong....
By the way, regulations are not laws. SEC enforces regulations that the SEC writes, that are its interpretation of the law written by congress. Only a judge can decide if the reg is legitimate and if it was breaking the law. Most people and companies do not have the resources to go to court. And they frequently get screwed by Gov officials because of it, or murdered by a cop.....who is having a bad day, that gets away with it because he or she is a cop.
I am sure many good people try their best to do good jobs at the SEC. But it is hard to get the job done while hand cuffed.....
And don't even get me started about lawyers LOLOL.
What is wrong with being able to keep and hold my shares till hell freezes over in hopes the company survives and gets going again? What gives the SEC the right to destroy my shares or the value of them? The market already knows the firm is late reporting.
Now if they had tried to pump and dump millions of shares with out financials? Yes it is fair game.
I think lotteries should be illegal. And Tobacco....
I assume you knew STLT was two years' delinquent with its filings? The company was breaking the law. The law in question is the Securities Exchange Act of 1934, known familiarly as the Exchange Act. It was aware of its obligations, and was in fact sent a delinquency letter at the end of September 2019. It did not respond.
If you want to be pissed off, you should be pissed off at the company, and at yourself. If the company didn't have the money to file, it should have filed a Form 15 to terminate registration voluntarily. I'd add that if it didn't have the money to file, why would anyone want to buy its stock? It isn't all THAT expensive.
Personally I think the SEC gets paid off by big money to ignore obvious toxic note pump and dump scams on a regular basis, and gets paid to kill off others that will not make deals with Toxic note people.
That is total bullshit. The SEC has in fact been doing a good deal to try to get the toxic funders out of the market in the last six years and more.
Yes, but I am the one that got screwed out of any chance of the company being revived, screwed because the firm simply does not have funds to get fully reporting right now, screwed because the SEC decided to declare to declare my STLT shares worthless. So much for the capitalist free market, my ass.
I don't need the SEC saving me. No one is saving people from Billion dollar publicly traded Drug firms legally peddling DEADLY Opioids for decades that killed 10's or thousands yearly while they make billions doing it for shareholders. Why not revoke those toxic drug firm shares? Novartis paid an over a $100 Mil dollar fine a week ago for felony fraud for bribing doctors. Why are their shares trading?
Who went to jail? Who was sent to death row for all for those murders by opioid drug peddlers on Wallstreet???
There are zombie stocks out there that are a decade or more old still trading and they nail one that still had retail product, Venodol selling online at Walmart last year and that still has inventory on Ebay being sold today, that was still fully reporting in 2018.
All STLT did was be late filling financials. They never did any pump and dumps, or Prs or promo pumps, like so many zombie stocks do.
I have used the Venodol STLT product they produced and it works great. I bought myself a 10 year supply, it works that well. So did others I know.
Making my DTC held STLT shares trapped and unsalable sucks any way you look at it. It makes it impossible for the firm to get back into business as public firm, and for shares to ever even possibly have any value again or be tradeable.
I have STLT shares going back 11 years. Never sold one. Bought them all at retail. It may be time for me to raise hell and go after the SEC by shaking up legislators.... Hmm, I think I may just finally do that. I was the one of the voices that got the Lemon car law passed decades ago.
SEC lets hundreds of toxic pump and dumps wipe shareholders out and they waste time on this one??? Something stinks in the SEC, IMHO.
It is nothing more than a big Money grab by folks that control the SEC IMHO.
They want to kill of any chance of small firms succeeding and getting funding here in the OTC, or of firms having time to get a fresh start. It is obvious from Public records that SEC lobbyists want to close the OTC down.
Just because a firm is inactive (late reporting), should not give the SEC the right to destroy my shares and their value.
Custodian could have come along and revived it was completely dead.
SEC has a big money lobbyist led agenda and I plan to fight them. The missed Enron, which I figured out was a scam long before they woke up. They let Madoff run a Ponzi scheme for over a decade. But no they waste time forking around with a quite little company that is behind on financials.
No I am not buying that BS. Time to change the regs and protect small stock investors the right way. Start by Outlaw toxic MOB-style predatory loans to start with.
Time to Make OTC Great Again.
Personally I think the SEC gets paid off by big money to ignore obvious toxic note pump and dump scams on a regular basis, and gets paid to kill off others that will not make deals with Toxic note people.
This is entirely the fault of STLT. They were two years behind with their required periodic filings. The SEC sent a delinquency letter last September, which the company ignored.
And so its registration will be revoked.
Note worthy that the 2 CEOs, Directors of STLT still own 2/3rds of the OS shares, from funding the company with their own cash, that they never pumped and dumped.
I guess the SEC is just starting to nuke everything in OTC now down to grey sheets like they were talking about doing a year ago, which serves no useful purpose for real shareholders like me, IMHO except to screw us over and reduce any bid and ask transparency.
But lets push worthless lottery tickets and milk the sheep in state lotteries..
Looking around Ebay I see a whole lot of new products like STLT's Venodol for sale online in the US now that were not available when STLT Venodol came out.
https://www.ebay.com/itm/Rheumatoid-Arthritis-Joint-Pain-Relief-Sore-Muscle-Patch-with-Scorpion-Venom/143403516157?_trkparms=aid%3D1110006%26algo%3DHOMESPLICE.SIM%26ao%3D1%26asc%3D227674%26meid%3Da4c922e3104d4162a929185217099600%26pid%3D100005%26rk%3D5%26rkt%3D12%26mehot%3Dpf%26sd%3D253913930052%26itm%3D143403516157%26pmt%3D1%26noa%3D0%26pg%3D2047675%26algv%3DSimplAMLv5PairwiseWebWithDarwoV2BBEV2b&_trksid=p2047675.c100005.m1851
The one above is based on Scorpion venom. STLT Venodol used Cobra snake venom.
The one below is based in bee venom.
https://www.ebay.com/itm/Rheumatoid-Arthritis-Joint-Pain-Relief-Sore-Muscle-Plaster-Patch-with-Bee-Venom/143480122585?_trkparms=aid%3D1110006%26algo%3DHOMESPLICE.SIM%26ao%3D1%26asc%3D227674%26meid%3D53dbf5df5652416b9284d96cee6f9c43%26pid%3D100005%26rk%3D2%26rkt%3D12%26mehot%3Dpf%26sd%3D143403516157%26itm%3D143480122585%26pmt%3D1%26noa%3D0%26pg%3D2047675%26algv%3DSimplAMLv5PairwiseWebWithDarwoV2BBEV2b&_trksid=p2047675.c100005.m1851
Well that is a shame. They actually had a $500,000 inventory of a working roll on pain killer that Walmart was selling almost 2 years, called Venodol.
Great product. It actually worked/works very well. Much safer than dangerous blood thinning Ibuprofen and other NSAIDS or steroids like prednisone, where a topical roll on can be used, say for knee or ankle pain. Way safer than opioids too.
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4b9dfe7e-ccd1-4115-bc06-07e63eee4712&type=display
I bought several years worth of it from Walmart for myself when they still had it. So did some others that had found nothing as good as it in 10 years.
Several Ebay sellers still have some for sale.
https://www.ebay.com/i/124073450993?chn=ps
So its going to gray sheets now?
Walmart must have sold out of it:
https://www.walmart.com/ip/Venodol-Roll-on/881335784
Is a dead link now.
STLT SEC Suspension for severely delinquent Financials:
https://www.sec.gov/litigation/suspensions/2020/34-89252.pdf
Order:
https://www.sec.gov/litigation/suspensions/2020/34-89252-o.pdf
Admin. Proceeding:
https://www.sec.gov/litigation/admin/2020/34-89253.pdf
The stock is too cheap for a 9 Mil share float to sell this low
And 66% of the OS is owned by one company with 4 major shareholders.
Ill buy and add on dips for the day they do something with it again, 1,2 years or this summer, who knows. The CEO was a massive funder and shareholder.
I have seen stocks like this trade at this price with 100 times as many float shares.
Good luck with your investments
no I ended up selling to take a loss. The company is not even reachable by any means, I just assumed to take the loss.
Since I have seen no volume selling for years here I assume you are still long too?
Signs of life on the ticker here. $500 buy at the ask out of no where.
Maybe not dead after all? Big buy at the ask today.
Found some more recent news on STLT Biotech with only 9.9 Mil shares in the OS.
But we had missed this news, till just now IIRC?
https://www.healthcaretechoutlook.com/news/celtic-biotech-iowa-licenses-a-propitious-therapy-for-acute-and-chronic-nephropathy-nid-39.html
Going to try an find someone that knows what is going on.
More signs of life here day 2, and someone bought $1200 in shares recently at the ask at an 80%(?) premium with news.
Walmart is still their Venodol, I bought some more recently.
Could the CEO be doing a merger? Buyout?
What happened to Celtic Biotech? They own it and it was valued at 10 times the current market cap.
Less that 10 mil share OS, insiders, the ex and current CEO hold about 2/3rds of the issued shares.
First time they went dark for 6 months, the stock rallied 500% when the reports were corrected and update.
$STLT heads up, No one spends $1200 buying a dead, no volume stock, at a 50% premium with out good reason!!!
Now a paint job at the bid.
Something is going on behind the veil!!! This one is waking up at the floor at .01 and was $2/share not long ago.
Real Biotech with a book value last reported at 10 times the current...
No one spends $1200 buying a dead stock at a 50% premium with out good reason!!!
Now a pain job at the bid.
Something is going on behind the veil!!!
A large ask slap at a 50% premium over the bid.
Its Alive!!!!! Snakes alive, LOL.
An ask slap
Signs of life???
I bought some Venodol last week.
Phone and website work, but no one answers the phone
Website says they are sold out of STLT Venodol, but they had $500,000 of it at cost in Inventory last year.
Just ordered some using Amazon Prime, they have it in stock, as does Walmart.
No share printing, or selling, but no phone voice mail, just rings, and email replies or bounces.
My guess is they are working on financials, financing, and news. But it may be a while. If I get bored I may try to reach then via other routs, but it looks like they are in gaged quite period.
Way too many assets sitting in this for it not to be trading at 30-50 times the bid.
Very odd and unusual what has happened here.
Interesting rise going on here.
10-Q coming. maybe?
Ask is super thin, and what looked like a toxic seller vanished.
Back in .11 in seconds with any buying volume.
I was wondering whose bid that was.
This stock has been dead, twice before. Once when the oil and gas well partners they had went belly up because Nat Gas prices fell 80% back around 2010. Cris picked up the ball and took over and made it a biotech, the current CEO was one of the main money investors before Cris turned over the reigns to John.
The second time it died, was when the auditors killed it for about 6 months, 10-K was late to redo the prior one, and when it was all said and done the prior 10-K had undervalued a company they had bought and the stock soared to about .86/share, LOL. Then they came out with Venodol, which works great. They did have a loss on another biotech they invested in before the Venodol came out...
I just don't think we have seen the last of STLT here. The CEO did release recent year email saying they are working on things, as in alive and kicking.
Was doing some DD here today. Tried to call the 877 order number direct, the number is no longer in use, the STLT home office did not answer (no working voice mail when I called, but the number did work/rang).
Walmart and Amazon still have the Venodol for sale. I am thinking of buying a few years of the product, as the reviews are great, and I used the product and found it work great, still have some, and a friend of mine bought a whole case for his wife, as she tried it and said it worked better than anything she had tried in 10 year, WOW!!! She has nerve damage fake pain from Shingles years ago....
What I found interesting is this link
https://www.venodol.com/product/product-venodol-topical-roll-on/
Says they out of inventory already? They had about $500,000 of it in inventory at STLT on the financials when they went to market.
And while the Venodol phone number, 877 number is dead, the web site is still up. I emailed an old email I have for the Founder (Cristopher) who is one of the 2 largest shareholders and founder, he and John (current CEO) own about 70% of the OS, to see if that email still works.
My gut tells me they just are doing major cost cutting, and re-organizing, and the current ask is a steal, but for now I will continue my DD hunt. Still very long, with way too much invested here to give up. And the new CEO, near as I could tell from reading the SEC filings bank rolled much of the debt. Which is why there is no trading volume or share dumping.
Still, be nice to get an answer at the company phone, or email.
yes I am on that same mailer and got the same email, so yes its a buy right here.
I got an email update from the STLT CEO, the one that most of the convertible debt is owed to and one of the two insiders holding 66% of the restricted OS shares. It was amass email from him to those in the company database that signed up over the years for updates.
Basically said he and the company are still working the plan, operating, working on possible deals, drug trials, better financing and so on, and a Happy New Year wish with a thanks to faithful longs hanging in there.
Right now this is so way oversold, and way way way undervalued I am a buyer of share dumps here this low. Still under 10 Mil shares in the float. Assets were valued at something like 10-15 times the market cap today. Float is valued at $80,000 today at the best bid, for a biotech with a real OTC- pain killing rub on product selling at Walmart.
$100 in trade volume?
LOL
Partying in the streets yet?
More of the usual eh?
GLTA & JMO
Make what stuff up? It is up 467% today. That should wake up this dead looking story here?
Happy Holidays STLT Longs!
.OOPs
LOL
How long can it go?
I cant even make this stuff up.
GLTA & JMO
The Bulls are back now, bid up 150% above the lowest trade today, and no sellers, and ask is almost 10 times the lowest trade.
Bids already at .0050 now. I am also bid shopping here.
Im bidding 400K shares @.004 to see what I can get, I now have a lot more cash to buy stuff
The bears are back, down 70% or 95% from the ask to the low of the day. Somebody got some bargains today. 1/4 mil share dump, tax loss/estate liquidation, all in one trade. Maybe even margin call on other stuff liquidated the account...
At the .002 low today and just under 10 mil shares in the float...
10,000,000 x .002 = $20,000 value for the entire float. That is just nuts.
They had $500,000 in Venodol Inventory (10-Q), 95% of which had not even been reported as revenue yet, this year, and Walmart selling the product.
Toxic MM AEXG is on the best bid at .0004 now and on the ask at .015
That spread looks like the grand canyon now. I doubt this sell was convertible debt with the 10-Q being so late? The book value of the Celtic Biotech subsidiary was $3 Million dollars. The CEO and prior CEO combined owned the other 20 Mil shares.
Market cap at .0020 is $60,000
Convertible debt fear is one issue, they have a lot of it, but the two founder CEOs own 66% of the OS, and the current CEO is the one that has been funding it, so he has little reason it seems to PR/pump the stock with fake news.
Recent lay offs of officers is a concern, very late now on the last SEC financial is a big concern.
The Venodol has already been marketed and is sold on line and at stores by Walmart and Amazon. They have patents. The Celtic Biotech company they bought was valued at 3 Million dollars.
With the stock price at .01 and only 30 Mil shares issued, the market cap is now $300,000 or 10% of what they paid for just one company they bought. One of the operations won a $300,000 R&D grant just about 6 months ago. This was at $2, 2 years ago, and .25 earlier this year. Float is just under 10 mil shares, and tightly held as the volume has died down here, not even any tax loss selling now.
And SEC filling, financials would rally it.
Happy Holidays!
A couple things, while the rub may work great, it needs to be marketed and that takes a lot of money that they dont have, thats the big concern. Secondly they have all those other projects in the pipeline that we havent heard anything about for a while. So while there is clearly pent up potential, get it realized is the challenge. Which is why the stock price is where its at, but still lower than I would expect.
Two years ago the 10-K was delayed and about 6 months later it was filed and the stock price exploded. I agree the market cap and float are super tiny, way way under valued. They have an awesome rub on pain killer selling at Walmart too. Based on Cobra venom. I have a friend who has nerve damage from a case a shingles ages ago, and she had tried everything, and the STLT Venodol worked so well she bought an entire case of it. I use it for Rheumatoid Arthritis pain flares
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2020
|
Created
|
02/02/10
|
Type
|
Free
|
Moderators |
Market Value1 | $9,355,615 | a/o Aug 29, 2016 | |
Authorized Shares | 4,000,000,000 | a/o Nov 04, 2014 | |
Outstanding Shares | 15,856,974 | a/o Aug 02, 2016 | |
-Restricted | Not Available | ||
-Unrestricted | Not Available | ||
Held at DTC | Not Available | ||
Float | 2,342,931 | a/o Aug 02, 2016 | |
Par Value | 0.001 |
VStock Transfer LLC |
Shareholders of Record | 77 | a/o Aug 02, 2016 |
|
Celtic Biotech Iowa Inc., is developing novel therapeutic products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.
Celtic Biotech Iowa Inc. is a subsidiary of Spotlight Innovation Inc.
Read the press release here.
Additional information about Celtic Biotech here.
Management
Cristopher Grunewald, CEO
Mr. Grunewald is a financial executive and entrepreneur with background in the healthcare and biotechnology sectors, private equity and investment banking. He has been involved in all stages of the commercialization of healthcare IP developed by premiere research and development institutions.
Dr. David Hostelley, CFO
Dr. Hostelley has twenty years as a consultant in the health field, and has served as CEO, CFO and board member of several publicly traded companies. Dr. Hostelley is a CPA (inactive) licensed by the state of Ohio. He earned his Ph.D. in management while a lecturer in the MBA Program of Baldwin-Wallace College, and has lectured in Accounting and Management for Walsh University, North Canton, Ohio.
Jeffrey Stein, Esq., Securities Counsel
Mr. Stein serves as securities counsel for Spotlight Innovation. He has over fifteen years of experience providing high quality, personalized attention to public companies, including more than thirty reverse mergers, IPOs and APOs.
Rene Erickson, Corporate Communications
Mr. Erickson has three decades of corporate communications experience across diverse industries including healthcare, information technology, aviation and academia.
Mike Reysack, Investor Relations
Mr. Reysack leads Investor Relations for Spotlight Innovation. He has extensive experience cultivating and managing relationships with financial stakeholders, including fifteen years as an Investor Relations consultant and business strategist for venture and early stage companies, providing effective communications between companies and the financial community.
Special Advisor
Jerry Cirino
Mr. Cirino is a healthcare technology executive with extensive background in medical devices, distribution and healthcare information in private equity and public environments. His experience includes management of complex growth and transition environments including M&A, integrations and global operations, and he is a proven consultant in transaction evaluation, due diligence and strategic planning.
Partner Firms
Auditor
Transfer Agent
VStock Transfer, LLC, Woodmere, NY
Law Firms
Davis Brown Law Firm, Des Moines, IA
JMS Law Group, New York, NY
Eilers Law Group, Miami, FL
Whitfield & Eddy, P.L.C., Des Moines, IA
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |